

525 Rec'd PCT/PTO 18 DEC 2000

FORM PTO-1390
(REV. 1-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

BET 00/1188

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/719978

INTERNATIONAL APPLICATION NO.

PCT/FR99/01446

INTERNATIONAL FILING DATE

16 June 1999

PRIORITY DATE CLAIMED

16 June 1998

TITLE OF INVENTION

METHOD FOR OBTAINING MODIFIED POLYSACCHARIDES

APPLICANT(S) FOR DO/EO/US

Steven BALL

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:

Sequence Listing in computer readable form with disk.

International Preliminary Examination Report.

Search Report.

Application Data Sheet.

U.S. APPLICATION NO. (if known, see 37 CFR 1.51) 09/719978		INTERNATIONAL APPLICATION NO. PCT/FR99/01446		ATTORNEY'S DOCKET NUMBER BET 00/1188	
--	--	---	--	---	--

<p>17. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO 860.</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO 710.</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) 690.</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) 100.</p> <p style="text-align: center;">ENTER APPROPRIATE BASIC FEE AMOUNT =</p> <p>Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 15%;">CLAIMS</th> <th style="width: 15%;">NUMBER FILED</th> <th style="width: 15%;">NUMBER EXTRA</th> <th style="width: 15%;">RATE</th> <th style="width: 15%;">\$</th> <th style="width: 20%;"></th> </tr> <tr> <td>Total claims</td> <td>18 - 20 =</td> <td>0</td> <td>x \$ 18.</td> <td>\$ 0</td> <td></td> </tr> <tr> <td>Independent claims</td> <td>5 - 3 =</td> <td>2</td> <td>x 80.</td> <td>\$ 160</td> <td></td> </tr> <tr> <td colspan="4">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ 270.</td> <td>\$</td> </tr> <tr> <td colspan="4" style="text-align: right;">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$ 1,150</td> <td></td> </tr> <tr> <td colspan="4">Reduction of 1/2 for small entity</td> <td>\$</td> <td></td> </tr> <tr> <td colspan="4" style="text-align: right;">SUBTOTAL =</td> <td>\$ 1,150</td> <td></td> </tr> <tr> <td colspan="4">Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</td> <td>\$</td> <td></td> </tr> <tr> <td colspan="4" style="text-align: right;">TOTAL NATIONAL FEE =</td> <td>\$ 1,150</td> <td></td> </tr> <tr> <td colspan="4">Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +</td> <td>\$</td> <td></td> </tr> <tr> <td colspan="4" style="text-align: right;">TOTAL FEES ENCLOSED =</td> <td>\$ 1,150</td> <td></td> </tr> <tr> <td colspan="4"></td> <td>Amount to be refunded:</td> <td>\$</td> </tr> <tr> <td colspan="4"></td> <td>charged:</td> <td>\$</td> </tr> </table>	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$		Total claims	18 - 20 =	0	x \$ 18.	\$ 0		Independent claims	5 - 3 =	2	x 80.	\$ 160		MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ 270.	\$	TOTAL OF ABOVE CALCULATIONS =				\$ 1,150		Reduction of 1/2 for small entity				\$		SUBTOTAL =				\$ 1,150		Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$		TOTAL NATIONAL FEE =				\$ 1,150		Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$		TOTAL FEES ENCLOSED =				\$ 1,150						Amount to be refunded:	\$					charged:	\$	<p>CALCULATIONS PTO USE ONLY</p>
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$																																																																											
Total claims	18 - 20 =	0	x \$ 18.	\$ 0																																																																											
Independent claims	5 - 3 =	2	x 80.	\$ 160																																																																											
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ 270.	\$																																																																										
TOTAL OF ABOVE CALCULATIONS =				\$ 1,150																																																																											
Reduction of 1/2 for small entity				\$																																																																											
SUBTOTAL =				\$ 1,150																																																																											
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$																																																																											
TOTAL NATIONAL FEE =				\$ 1,150																																																																											
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$																																																																											
TOTAL FEES ENCLOSED =				\$ 1,150																																																																											
				Amount to be refunded:	\$																																																																										
				charged:	\$																																																																										

a. ☒ A check in the amount of \$ 1,150 to cover the above fees is enclosed.


b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required by 37 CFR 1.16 and 1.17, or credit any overpayment to Deposit Account No. 25-0120. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

December 18, 2000

SEND ALL CORRESPONDENCE TO:

<p>Young & Thompson 745 South 23rd Street 2nd Floor Arlington, VA 22202 (703) 521-2297</p>	<p style="text-align: center;">CUSTOMER NO. 000466</p> <div style="text-align: center;">  SIGNATURE Benoit Castel NAME 35,041 REGISTRATION NUMBER </div>
--	--

09/719978

525 Rec'd PCT/PTO 18 DEC 2000

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Steven BALL

Serial No. (unknown)

Filed herewith

METHOD FOR OBTAINING
MODIFIED POLYSACCHARIDES

PRELIMINARY AMENDMENT

Commissioner of Patents

Washington, D.C. 20231

Sir:

Prior to calculation of the filing fee, please amend
the above-identified application as follows:

IN THE CLAIMS:

Claim 4, lines 1 and 2, change "any one of the
preceding claims" to --claim 1--.

Claim 5, lines 1 and 2, change "any one of the
preceding claims" to --claim 1--.

Claim 6, lines 8 and 9, change "any one of the
preceding claims" to --claim 1--.

Claim 15, line 2, cancel "or 14".

Add the following new claim:

--18. Cloning and/or expression vector comprising
a nucleotide sequence as defined in claim 14.--

Respectfully submitted,

YOUNG & THOMPSON

By

Benoit Castel

Benoit Castel
Attorney for Applicant
Registration No. 35,041
745 South 23rd Street
Arlington, VA 22202
Telephone: 703/521-2297

December 18, 2000

09719978-04301

5/prts

09/719978

525 Rec'd PCT/PTO 18 DEC 2000

PCT/FR99/01446

WO 99/66056

- 1 -

METHOD FOR OBTAINING MODIFIED POLYSACCHARIDES

The present invention relates to a method for obtaining plants which produce modified polysaccharides (such as starch or glycogen), to these modified polysaccharides extracted from these plants, and to the products prepared from these modified polysaccharides.

Starch is the energetic storage polyoside in plants. It constitutes the main calorific intake of the animal and human diet, and is also a major source of plant raw material for nondietary uses. Starch is composed of two distinct polysaccharide fractions: amylose and amylopectin. Amylose, which represents the minor fraction of starch, consists of glucose residues joined together via α -1,4 linkages and exhibits less than 1% branching. Amylopectin, which represents the major fraction of starch, consists of glucose residues joined together via α -1,4 linkages and exhibits approximately 5% branching, which consists of glucose residues linked to the principal polymer via an α -1,6 linkage. The asymmetric distribution of the branching of amylopectin is responsible for the unlimited growth of the molecules and, consequently, of grains of starch, and also accounts for most of the physicochemical properties of starch.

The biosynthesis of starch depends on a pathway, the main biochemical steps of which are the synthesis of ADP-glucose, followed by the transfer of this precursor to the α -1,4 position on a glucan by (ADP-glucose: 1,4- α -D-glucan 4- α -D-glucosyl)transferases, the polymer formed being branched by the action of so-called branching enzymes: 1,4- α -D-glucan 6- α -D-(1,4- α -D-glucano)-transferases. Appended Figure 1 is a simplified scheme of the metabolism of starch so far known to those skilled in the art.

Known plant α -1,4 glucanotransferases (or 4- α -D-glucanotransferases) are commonly referred to as "D

09/719978 04250

enzymes", for "disproportionating enzymes". They catalyze the transfer of glucan from one 1,4- α -glucan molecule to another (intermolecular transglycosylation). The rules of action of the D enzyme on oligosaccharide substrates are represented schematically as follows:

Scheme: Example of disproportionating activity by the D enzyme on maltotriose

Acceptor (n)	Donor (x)	↔	Product (n + 2)	+ Donor -2
*G~G~GOH	+ *G~G~GOH	↔	*G~G~G~G~GOH	+ *GOH
*G~G~G~G~GOH	+ *G~G~GOH	↔	*G~G~G~G~G~G~G OH	+ *GOH
*G~G~GOH	+ *G~G~G~G~G~G~G OH	↔	*G~G~G~G~G OH	+ *G~G~G~G~G
OH				
*G~G~G~G~GOH	+ *G~G~G~G~GOH	↔	*G~G~G~G~G~G~G OH	+ *G~G~G OH

Maltose cannot be used as a donor substrate, and only a linkage at the end of the maltotriose can be attacked. In addition, the first linkage on the nonreducing side and the penultimate linkage on the reducing side are resistant to the action of the enzyme.

Takaha et al. have reported, at the AAB (Association of Applied Biologists) Congress which was held from 6 to 8 April 1998, in Edinburgh, UK (congress on the subject: "Production and use of starch"), that potatoes with no D enzyme grow more slowly than control potatoes and that, despite this, the content of starch present in the tubers, and its composition, appear to be normal with regard, in particular, to the appearance of the starch grains by optical or electron microscopy, the proportions of amylose and amylopectin, the molecular weight of the debranched amylopectin and the number and length of the α -1,6 branchings. Takaha et al. have concluded from this that the D enzyme does not have a direct role concerning the structures and amounts of starch produced, but plays a role in the growth of the plant and its development, the

amylopectin and amylose being used as donor molecules for the transfer of maltooligosaccharide to glucose, thus allowing the breaking up and solubilization of starch grains (Takada et al., 1998).

Surprisingly, the authors of the present invention have discovered that α -1,4 glucanotransferases, and in particular D enzymes, are in fact involved in the biosynthesis of starch by transferring oligosaccharides to an amylopectin precursor. These enzymes can, in particular, transfer oligosaccharides originating from the pool of oligosaccharides produced *in vivo* by debranching of the amylopectin precursor during amylopectin maturation. They can in particular transfer oligosaccharides which may contain, for example, from 2 to 20, in particular from 2 to 6, glucose residues. Appended Figure 2 shows the role of the D enzyme in the starch metabolism cycle, as discovered by the authors of the present invention.

This discovery has been exploited in order to modify, as a function of the level of active α -1,4 glucanotransferase enzyme present, the length distribution for the chains of amylopectin, which is present in particular in the storage organs of plants. The invention also applies to glycogen, which is present in a smaller amount than amylopectin in plants, but which can be found, for example, in sweetcorn seeds, allowing, in the same way, the modification of the length distribution for the chains of glycogen.

A subject of the present invention is, therefore, the use of a nucleic acid encoding an α -1,4 glucanotransferase enzyme or a sequence which is the antisense sequence to said sequence encoding an α -1,4 glucanotransferase enzyme, for modifying the length distribution for the external chains of starch (i.e. of amylopectin and/or of amylose) or of glycogen.

A subject of the present invention is more particularly a method for modifying the length distribution

09719978.042501

for the chains of the amylopectin of a starch, or for the chains of a glycogen, in which the activity of an α -1,4 glucanotransferase enzyme is increased or decreased in the cells of a plant such that said plant produces a modified starch which differs from the starch produced naturally by the plants, by the length distribution for the chains of the amylopectin, or produces a modified glycogen which differs from the glycogen produced naturally, by the length distribution for its external chains.

According to a first embodiment of the invention, the level of expression of endogenous α -1,4 glucanotransferase enzyme is decreased so as to cause the production of a starch comprising an amylopectin which is enriched in chains containing less than 6 glucose residues, with respect to a starch produced naturally. The decrease in the expression of an endogenous α -1,4 glucanotransferase enzyme can be in particular produced according to the method comprising the steps consisting in:

- a) constructing an expression vector comprising an antisense nucleotide sequence of the gene encoding said endogenous α -1,4 glucanotransferase enzyme;
- b) transforming a plant cell with said expression vector;
- c) regenerating the plant from the cell transformed in step b, said transgenic plant thus obtained producing a starch comprising an amylopectin in which the chain length distribution is modified, in particular in the sense of an enrichment in chains containing less than 6 glucose residues.

Advantageously, said plant cell transformed according to step b) is also transformed with antisense nucleotide sequences of the genes encoding enzymes which affect the distribution of the length of the oligosaccharides produced in the metabolism of starch, such as phosphorylases and amylases.

Another possibility for decreasing the activity of

09719978-042501

the α -1,4 glucanotransferase enzyme in plant cells is to express ribozymes, which are RNA molecules which act as enzymes which catalyze specifically the cleavage of transcripts encoding the α -1,4 glucanotransferase enzyme, by techniques known to those skilled in the art (EP 321 021).

It is also possible to obtain a plant having a modification of the expression of α -1,4 glucanotransferase enzyme, by the so-called "transwitch" method described in WO 90/12084.

The activity of the endogenous α -1,4 glucanotransferase enzyme can also be decreased by mutagenesis of the plant cells, either by U.V. irradiation or with a chemical mutagenic agent, or by insertion of transposons. The transposable elements have the capacity to disturb the expression of genes into which they are inserted, and to generate deletions, rearrangements and mutations at the target locus (McClintock et al., 1950).

One transposon mutagenesis technique which can be advantageously used is Mutator transposon mutagenesis confirmed by reverse genetic screening (Bensen et al., 1995) (Das et al., 1995). This technique implements the steps consisting in crossing a "Mutator" line with hybrids of the plants of interest, and then screening the F1 plants obtained by PCR with a primer specific for the transposons and a primer specific for the nucleotide sequence encoding the α -1,4 glucanotransferase enzyme. The F2 seeds obtained from the F1 screened plants make it possible to produce plants the phenotype of which is then analyzed.

According to a second embodiment of the invention, the level of expression of α -1,4 glucanotransferase enzyme in the plant is increased so as to cause the production of a starch comprising an amylopectin which is enriched in chains containing at least 9 glucose residues, with respect to a starch produced naturally, said α -1,4 glucanotransferase enzyme being identical to the endogenous

0934978 04501

α -1,4 glucanotransferase enzyme or being of heterologous origin.

The increase in the level of α -1,4 glucanotransferase enzyme can in particular be produced according to the method comprising the steps consisting in:

a) constructing an expression vector comprising a nucleotide sequence encoding an α -1,4 glucanotransferase enzyme, which can be an α -1,4 glucanotransferase enzyme identical to the endogenous α -1,4 glucanotransferase enzyme, or which can be of heterologous origin;

b) transforming a plant cell with said expression vector;

c) regenerating the plant from the cell transformed in step b), said transgenic plant thus obtained producing a starch comprising an amylopectin in which the chain length distribution is modified, in particular in the sense of an enrichment in chains containing at least 9 glucose residues.

Advantageously, said plant cell transformed according to step b) is also transformed with nucleotide sequences encoding enzymes which affect the distribution of the length of the oligosaccharides produced in the metabolism of starch, such as phosphorylases and amylases. Preferably, the α -1,4 glucanotransferase enzyme targeted is a D enzyme.

Said nucleotide sequence encoding an α -1,4 glucanotransferase enzyme can be of heterologous origin. It can thus correspond in particular to an enzyme chosen from the D enzyme of potato (Takaha et al., 1993) or the D enzyme of *Chlamydomonas reinhardtii*.

Also included in the invention is a nucleic acid comprising a nucleotide sequence chosen from the sequence SEQ ID No. 1, a homologous sequence and a fragment of this sequence encoding a protein having α -1,4 glucanotransferase enzymatic activity.

The invention also comprises the sequences

09349978 042501

complementary to the sequence SEQ ID No. 1, or to its homologues and fragment, which can be used as antisense sequences in the method of the invention.

The sequence SEQ ID No. 1 represents a fragment of genomic DNA of the gene encoding the D enzyme of *Chlamydomonas reinhardtii*.

The expression "homologous nucleotide sequence" is intended to mean any nucleotide sequence which differs from the sequence SEQ ID No. 1 by substitution, deletion and/or insertion of a nucleotide or of a small number of nucleotides, at positions such that these homologous nucleotide sequences encode homologous polypeptides as defined hereinafter.

Preferably, such a homologous nucleotide sequence is at least 75% identical to the sequence SEQ ID No. 1, preferably at least 85%, more preferably at least 95%.

Preferentially, such a homologous nucleotide sequence hybridizes specifically to the sequence complementary to the sequence SEQ ID No. 1, under stringent conditions. The parameters which define the stringency conditions depend on the temperature at which 50% of the paired strands separate from each other (T_m).

For sequences comprising more than 30 bases, T_m is defined by the equation: $T_m = 81.5 + 0.41(\%G+C) + 16.6 \log(\text{concentration of cations}) - 0.63(\%\text{formamide}) - (600/\text{number of bases})$ (Sambrook et al., Molecular Cloning, A laboratory manual, Cold Spring Harbor laboratory Press, 1989, pages 9.54-9.62).

For sequences less than 30 bases long, T_m is defined by the equation: $T_m = 4(G+C) + 2(A+T)$.

Under suitable stringency conditions, at which aspecific sequences do not hybridize, the hybridization temperature is approximately from 5 to 30°C, preferably from 5 to 10°C below T_m , and the hybridization buffers used are preferably solutions of high ionic strength, such as a 6xSSC solution, for example.

09719978-042504

The term "nucleotide fragment" is intended to mean any fragment of the sequence SEQ ID No. 1, or of the nucleotide sequences homologous to the sequence SEQ ID No. 1, which encodes a peptide or a protein having α -1,4 glucanotransferase enzymatic activity, as defined above.

A subject of the present invention is also a cloning and/or expression vector comprising a nucleotide sequence as defined above.

The construction of an abovementioned expression vector is within the scope of those skilled in the art, according to standard techniques. Said expression vector can contain an antisense nucleotide sequence of the gene encoding said endogenous α -1,4 glucanotransferase enzyme, according to the first embodiment of the invention, or a nucleotide sequence encoding an α -1,4 glucanotransferase enzyme, according to the second embodiment of the invention. The nucleotide sequence encoding an α -1,4 glucanotransferase enzyme is associated with elements which allow its expression in the plant, namely in particular a promoter and a transcription terminator.

The transformation of plant cells can be carried out by transferring the abovementioned vectors into protoplasts, in particular after incubation of the latter in a solution of polyethylene glycol in the presence of divalent cations (Ca^{2+}).

The transformation of plant cells can also be carried out by electroporation, in particular according to the method described in the article by Fromm et al., 1986.

The transformation of the plant cells can also be carried out using a gene gun which allows the projection, at very high speed, of metal particles coated with the DNA sequences of interest, thus delivering genes inside the cell nucleus, in particular according to the technique described in the article by Sanford (1988).

Another method for transforming the plant cells is

09319978-042504

that of cytoplasmic or nuclear microinjection.

According to a particularly preferred embodiment of the method of the invention, the plant cells are transformed by biolistics, i.e. by projection, by means of a particle gun, of microparticles coated with the nucleotide sequences to be transferred (J. Finner, 1992).

According to another embodiment of the method of the invention, the plant cells are transformed with a vector according to the invention, said cellular host being capable of infecting said plant cells by allowing the integration, into the genome of the latter, of the DNA sequences of interest initially contained in the genome of the abovementioned vector.

Advantageously, the abovementioned cellular host used is *Agrobacterium tumefaciens*, in particular according to the method described in the article by An et al., 1986, or *Agrobacterium rhizogenes*, in particular according to the method described in the article by Jouanin et al., 1987.

Preferentially, the transformation of the plant cells is carried out by transferring the T region of the tumour-inducing extrachromosomal circular plasmid Ti of *Agrobacterium tumefaciens*, using a binary system (Watson et al.).

In order to do this, two vectors are constructed. In one of these vectors, the T-DNA region was removed by deletion, with the exception of the right and left edges, a marker gene being inserted between them so as to allow the selection in the plant cells. The other partner of the binary system is an auxiliary plasmid Ti, this being a modified plasmid which has no more T-DNA but still contains the virulence genes *vir* required for the transformation of the plant cell. This plasmid is maintained in *Agrobacterium*.

Among the transcription terminators which can be used, mention may be made of the 35S polyA terminator of the cauliflower mosaic virus (CaMV), described in the

09719978-043501

article by Franck et al., (1980), or the NOS polyA terminator, which corresponds to the 3' noncoding region of the nopaline synthase gene of the plasmid Ti of the nopaline *Agrobacterium tumefaciens* strain (Depicker et al., 1982).

Among the transcription promoters which can be used, mention may be made in particular of:

- the 35S promoter, or advantageously the double 35S constitutive promoter (pd35S) of CaMV, described in the article by Kay et al., 1987;

- the PCRU promoter of the cruciferin gene of radish, allowing the expression of the associated sequences only in the seeds (or grains) of the transgenic plant obtained;

- the PGEA1 and PGEA6 promoters, corresponding to the 5' noncoding region of the seed storage protein genes GEA1 and GEA6, respectively, of *Arabidopsis thaliana* (Gaubier et al., 1993), and allowing specific expression in the seeds;

- the super-promoter PSP chimeric promoter (Ni M et al., 1995), consisting of the fusion of a triple repeat of a transcription-activating element of the promoter of the octopine synthase gene of *Agrobacterium tumefaciens*, of a transcription-activating element of the promoter of the mannopine synthase gene and of the mannopine synthase promoter of *Agrobacterium tumefaciens*;

- the rice actin promoter followed by the rice actin intron (PRA-RIA) contained in the plasmid pAct1-F4 described by Mc Elroy et al., 1991;

- the HMGW (High Molecular Weight Glutenin) promoter of barley;

- the promoter of the γ zein gene of maize (Pyzein), contained in the plasmid py63 and allowing expression in the albumen of maize seeds.

Among the plant cells capable of being transformed in accordance with the present invention, mention may be

09719978.043501
T05249.82657650

made of those of potato, of wheat, of maize and of rice.

A subject of the present invention is also a plant, or part of a plant, such as in particular potato, wheat, maize or rice, which produces a modified starch which differs from the starch produced naturally by the plants, by the length distribution for its external chains, or which produces modified glycogen which differs from the glycogen produced naturally, by the length distribution for its external chains, said plant or part of a plant being obtained by the method of the invention as described above.

The expression "part of a plant" is intended to mean in particular the storage organs naturally rich in starch, such as the seeds or tubers, or the organs naturally rich in glycogen, for example sweetcorn seeds. The expression "part of a plant" is also intended to mean the cells of said plant.

The invention also relates to a method for obtaining modified starch or modified glycogen, in which a starch or a glycogen is brought into contact with an α -1,4 glucanotransferase enzyme.

A subject of the present invention is more particularly a method for obtaining modified starch which differs from the starch produced naturally by the plants, by the length distribution for its external chains, in which:

- the modified starch is extracted from the plants, or parts of plants, obtained according to the method of the invention as described above.

- or a starch, extracted from plants, or parts of plants, and then solubilized, beforehand, is brought into contact with an α -1,4 glucanotransferase enzyme, in the presence of optionally modified polysaccharides or oligosaccharides.

The extraction of this starch is carried out according to standard techniques known to those skilled in the art. The solubilization of the starch is also known to

09719978.042504

those skilled in the art, and can be carried out by soaking and fractionation of the starch grain (Whistler et al., (1967)), or, for example, by heating. Alternatively, enzymes which break up starch, such as amylases, can be used.

According to one embodiment of the invention, said solubilized starch is brought into contact with an α -1,4 glucanotransferase enzyme, such as a D enzyme, in the presence of saccharides. Said saccharides can be, in particular, oligosaccharides which are chemically modified so as to modify the properties of the starch, for example its digestibility.

Advantageously, enzymes which affect the distribution of the length of the oligosaccharides produced in the metabolism of starch, such as phosphorylases and amylases, can be added to the α -1,4 glucanotransferase enzyme.

A subject of the present invention is also a method for obtaining modified glycogen which differs from the glycogen produced naturally (by plants or by an animal organism), by the length distribution for its external chains, in which:

- the modified glycogen is extracted from the plants, or parts of plants, obtained according to the method of the invention as described above.

- or a glycogen (of plant or animal origin) is brought into contact with an α -1,4 glucanotransferase enzyme, in the presence of optionally modified polysaccharides or oligosaccharides.

Said α -1,4 glucanotransferase enzyme, such as a D enzyme, brought into contact with the starch or glycogen, can originate from the same species of plant as that from which the starch is extracted, or can have a heterologous origin. The D enzyme can in particular be chosen from the D enzyme of potato (Takaha et al., 1993) or the 62 kD D enzyme of *Chlamydomonas reinhardtii* as defined hereinafter.

T 0 9 2 4 0 " 8 2 6 5 T 2 6 0

Advantageously, the D enzyme used is heat stable.

The D enzyme of *Chlamydomonas reinhardtii* is purified by the method comprising the steps consisting in:

- centrifuging the *Chlamydomonas reinhardtii* strain;
- precipitating the acellular fraction with protamine sulphate;
- passing the supernatant obtained in the previous step through anion exchange chromatography;
- subjecting the fraction not retained in the previous step to differential precipitation with ammonium sulphate;
- subjecting the supernatant obtained in the previous step to molecular sieve chromatography;
- concentrating the pellet obtained in the previous step, by cation exchange chromatography.

The purified D enzyme of *Chlamydomonas reinhardtii* thus obtained has a molecular weight of 62 kD. More generally, as a protein having α -1,4 glucanotransferase enzymatic activity, it is possible to use a protein or a peptide encoded by a nucleic acid comprising a nucleotide sequence chosen from the sequence SEQ ID No. 1, a homologous sequence or a fragment of this sequence.

A subject of the present invention is also the modified starch which differs from the starch produced naturally by the plants, by the length distribution for its chains, said modified starch being obtained by the method of the invention. In particular, the modified starch obtained by extracting and solubilizing the starch of plants, or parts of plants, and then bringing said solubilized starch into contact with an α -1,4 glucanotransferase enzyme, optionally in the presence of saccharides, contains an amylopectin in which the length distribution for the external chains is modified with respect to a starch produced naturally.

A subject of the present invention is also the

09719978-042501
T05240-826769

modified glycogen which differs from the glycogen produced naturally (for example by the plants, but also glycogen of animal origin), by the length distribution for its chains, said modified glycogen being obtained by the method of the invention.

The starch modified in accordance with the present invention can be used directly or hydrolyzed in order to produce oligosaccharides of interest (in particular glucose). The production of starch modified in accordance with the invention may make it possible to decrease the amounts of enzymes required for such a hydrolysis.

Moreover, the starch modified in accordance with the invention can be used in the manufacture of diverse foodstuffs, in particular as an additive which increases the viscosity or promotes the formation of a gel.

The starch modified in accordance with the invention can also be used in many industries: paper and board industry, adhesives industry, textile industry, pharmaceutical industry (for the formulation of medicines), etc.

The starch modified in accordance with the invention can also undergo other modifications, in particular chemical modifications such as acid treatment, oxidation, esterification, etc., before its use.

A subject of the present invention is also the use of this modified starch or of this modified glycogen for preparing derived products, in particular food products.

A subject of the present invention is also the products thus prepared comprising modified starch which differs from the starch produced naturally by the plants, by the length of its external chains, or modified glycogen which differs from the glycogen produced naturally, by the length of its external chains.

The figures and examples hereinafter illustrate the invention without limiting the scope thereof.

09719978 043501
T05240 8466T460

LEGENDS OF THE FIGURES:

Figure 1 represents a simplified scheme of the metabolism of starch so far known to those skilled in the art.

All the steps described are compartmentalized in the plast.

- ①. Phosphoglucomutase
- ②. ADP-glucose pyrophosphorylase
- ③. Soluble and bound starch synthetases
- ④. Branching enzymes
- ⑤. Phosphorylase
- ⑥. Amylases, debranching enzymes, maltases
- ⑦. Hexokinase

Glc = glucose; Pi = inorganic phosphate

Figure 2 represents a simplified scheme of amylopectin synthesis, in which the role of the D enzyme is demonstrated.

All the steps described are compartmentalized in the plast:

- ①. Conversion of G-6-P to G-1P by plastidial phosphoglucomutase
- ②. Synthesis of the glycosynucleotide precursor ADP-glucose by ADP-glucose pyrophosphorylase (AGPase)
- ③. Elongation by soluble starch synthetases (SSs)
- ④. Branching by branching enzymes (BEs)
- ⑤. Debranching by isoamylase (DBE) and release of oligosaccharides (MOS)
- ⑥. Reinsertion of the oligosaccharides produced by debranching, by the D enzyme.

WSP=water-soluble polysaccharides; MOS=maltooligosaccharides; G-6-P=glucose-6-phosphate; Glc=glucose.

The energetic cost of splicing by the DBE and the D enzyme described in this invention is 2 ATPs per glucan cleaved and reintroduced into the amylopectin in ⑥ (WSP^{III}). This cost ensues from the reactivation of the

09719978-04250
T09240" 8/66T260

glucose produced by the D enzyme into ADP-glucose. The dotted line drawn from WSP^{III} illustrates the possibility for the polysaccharide to be re-used as a substrate for elongation as long as the structure required for it to become insoluble in the grain has not been attained. The entry and exit from the cycle are illustrated by the arrows in bold lines, and consist, firstly, of ADP-glucose being synthesized and, secondly, of the polysaccharide being crystallized and becoming insoluble at the surface of the grain.

The synthesis of amylose occurs after the polysaccharide has become insoluble and takes place exclusively in the granule.

Figure 3A represents the distribution of the lengths of the soluble non-debranched oligosaccharides accumulated by the mutant strain JV45J of *Chlamydomonas reinhardtii*.

Figure 3B represents the length distribution for the chains of the debranched amylopectin of the wild-type *Chlamydomonas reinhardtii* strain.

Figure 3C represents the length distribution for the chains of the debranched amylopectin of the *Chlamydomonas reinhardtii* mutant strain JV45J.

Figure 3D represents the length distribution for the chains of the debranched amylopectin of "waxy" maize with the pure D enzyme of *Chlamydomonas reinhardtii* in the absence of oligosaccharides.

Figure 3E represents the length distribution for the maltotriose incubated with the pure D enzyme of *Chlamydomonas reinhardtii*.

Figure 4 represents the incorporation of maltooligosaccharides onto the amylopectin of the wild-type strain of *Chlamydomonas reinhardtii*.

Figure 5 represents the separation of the amylopectin and of the amylose of the starches of JV45J (*sta11-1*) and of 137C (wt) on CL-2B gel filtration

FOI 99-04501

chromatography. The mutant JV45J is represented by the radiolabelled starch (DPM) and the strain 137C is represented by the absorbance.

EXAMPLES:

The authors of the present invention have studied the biosynthesis of starch using a suitable model: the alga *Chlamydomonas reinhardtii* (Buléon et al., 1997). Specifically, this unicellular organism stores a starch which is identical to that stored in the albumen of cereals, and also contains the same enzymes for biosynthesis of starch.

The authors of the present invention have selected a novel mutant of the alga *Chlamydomonas reinhardtii* which accumulates small linear oligosaccharides and has a rate of starch synthesis decreased by 90% (Example 1).

The residual starch comprises a novel modified structure characterized by an enrichment in amylose and by an amylopectin, the ultrashort (approximately 2, 3 or 4 glucose residues) chains of which are overabundant in relation to the chains of mean length (approximately from 9 to 18 glucose residues) (Examples 2 and 3).

The authors of the present invention have also shown that this mutant lacked a 62kD protein normally present in the wild-type strains of *Chlamydomonas reinhardtii*, have identified this protein as being a 4- α -D-glucanotransferase (D enzyme) and have demonstrated novel functions of this D enzyme with respect to polysaccharides (Example 4).

These results can be exploited in order to obtain transgenic plants which produce modified polysaccharides (starch, glycogen) (Example 5).

The authors of the present invention have also demonstrated the role of the D enzyme in the degradation of maltooligosaccharides by phosphorylase (Example 6).

09719978 042501

The authors of the present invention have, moreover, succeeded in cloning the sequences encoding the D enzyme of *Chlamydomonas reinhardtii* (Example 7).

They have finally shown that the expression of the mutation may vary as a function of the physiological conditions (Example 8).

EXAMPLE 1:

Isolation of the mutant *sta 11* of *Chlamydomonas reinhardtii*

Selection of the strain JV45J of *Chlamydomonas reinhardtii*.

During UV mutagenesis (12% survival) carried out on the wild-type reference strain 137C of *Chlamydomonas reinhardtii*, 5×10^4 plaques of cells, lacking nitrogen, were screened using an iodine pulverization method (Delrue et al., 1992). All the strains containing less than 20% of the normal amount of starch accumulated by the strain 137C are detected by their yellow colouration, and were characterized. A sample of five wild-type strains and seven mutants is inoculated, as plaques of cells, on a medium lacking nitrogen. The plaques were pulverized twice after five days of incubation in continuous bright light. The yellow plaques contain less than 12% of the amount of starch accumulated by the black plaques. The olive-green colour observed in certain relatively colourless plaques suggests the existence of a residual starch enriched in amylose. Selected from these strains were those which displayed transcomplementation with mutants carrying *sta-1*, *sta6-1* :: ARG7, *sta7-1*::ARG7, *sta5-1*, which are defective for the loci encoding the large and small subunit of AGPase (*STA1* and *STA6*), the 88 kDa isoamylase (*STA7*), or plastidial phosphoglucomutase (*STA5*). Only one strain from the 5×10^4 colonies (JV45J) showing a 90 to 95% reduction in the amount of starch synthesized under accumulation

conditions (lack of nitrogen) was retained after this selection. This mutant was then crossed with a wild-type strain, and 257 products of meiosis were classified, respectively, into 119 strains of mutant phenotype for 128 clones of wild-type appearance.

A novel type of mutant (JV45J), which accumulates 4% of the normal amount of starch, could thus be isolated. In view of the segregation after crossing, the character responsible for the defective phenotype behaves as a Mendelian recessive character, and defines a novel genetic locus, named *STA11*, since the mutation transcomplements and recombines with all of the defects tested.

EXAMPLE 2:

Characterization of the polysaccharides of the mutant *stall*

The polysaccharides present in the strains carrying *STA11* were isolated. In addition to the granular starch, the *stall-1* mutants accumulate an equivalent amount (5%) of soluble glucans, maltooligosaccharides of small size (Figure 3A).

The simultaneous presence of a fraction of oligosaccharides and of the "low-starch" phenotype was found in all the strains carrying the mutation *stall-1* (n=50). The residual structure of the granular starch was measured by various techniques, including wide-angle X-ray diffraction analysis, transmission electron microscopy (TEM) and scanning electron microscopy (SEM), separation of the amylose and the amylopectin by gel filtration chromatography, NMR (Nuclear Magnetic Resonance) of the proton and enzymatic debranching on the amylose and the amylopectin thus purified.

1. The granular starch

The granular starch and the soluble glucans were

09719978 042504
T05240 "B" 657260

analysed separately. The starch dispersed in aqueous DMSO and delipidized by precipitation with four volumes of ethanol was resuspended in 10 mM NaOH in order to then be fractionated by molecular sieve chromatography on CL2B sepharose gel.

a) Amylose and amylopectin composition (gel filtration).

The separation of the amylopectin and of the amylose is carried out by gel filtration of the mutant strain JV45J and the wild-type reference 137C. The starch dissolved in 10 mM NaOH was fractionated by molecular sieve chromatography according to the method described by Delrue et al. (1992). A sample of each fraction was stained with iodine and the complete spectrum of the polysaccharide-iodine complex was recorded. Assays with amyloglucosidase revealed the presence of 30% of amylose (15% for the wild-type reference). In relation to the wild-type strain, the amylopectin is characterized by a λ_{\max} of the polysaccharide-iodine complex which has increased by 20 to 30 nm (from 550 to 570-580 nm). This latter characteristic is found in a large number of starches enriched in amylose.

The gel filtration profiles described show a doubling of the amount of amylose in the mutant with respect to the wild-type, and an apparent modification of the distribution of chain lengths of the amylose fraction. A new segregation analysis of the amylopectin and of the amylose on CL-2B gel filtration chromatography was carried out using 500 μ g of starch from JV45J (*sta11-1*) labelled with 14 C and 10 mg of starch from 137C. The results (Fig. 5) tend to confirm the data of the cosegregation study, namely a decrease in the length of the chains of amylose produced by the strain JV45J; the amylose appears, therefore, to be more abundant and lower in mass.

A radioactive count and the absorbance are determined for each fraction. The elution of the column is

carried out in 10 mM sodium hydroxide.

b) Shape of the granules and crystalline structure

The X-ray diffractograms show a change in the crystalline network from the wild-type A of high crystallinity towards a mixture of types A and B of much lower crystallinities. The shape of the granules is particularly modified and their overall size is reduced. In fact, the wild-type strain overall has grains with a smooth surface, whereas the mutant has grains of much smaller size with a rough and irregular grain surface.

2. The soluble glucans: maltooligosaccharide of small size

The fraction of soluble glucans (WSP) was subjected to triple extraction with methanol chloroform. The aqueous phase was lyophilized and the dry pellet redissolved in a buffer and fractionated by molecular sieve chromatography on a TSK-HW-50 column as has been described by Mouille et al., 1996. Unlike the soluble fractions (WSP) purified from isoamylase-deficient mutants, no phytoglycogen or other soluble polysaccharide of considerable mass was found. On the other hand, the WSP fraction accumulated by the *stall* mutants consists exclusively of relatively unbranched (less than 1.5% branching) oligosaccharides of low mass (Figure 3A).

EXAMPLE 3:

Demonstration of a modification of the amylopectin.

Enzymatic debranching with isoamylase and examination of the chain length distribution:

The amylose and amylopectin fractions obtained by molecular sieve chromatography then underwent enzymatic debranching with isoamylase, followed by electrophoretic separation of the debranched chains. The results

09749978-043504

illustrated in Figure 3 establish the novelty of the structure exhibited by the amylopectin of the strain JV45J. Specifically, the amylopectin exhibits an increase in chains conventionally absent from the structure.

APTS (8-aminopyrene-1,3,6-sulphonic acid) labelling was carried out on the reducing ends, before separating the chains as a function of their length on sequencing gel. Although no change is detected in the length distribution for chains of the amylose, significant modification of the distribution of the very short chain lengths is observed for the amylopectin (Figure 3C compared to Figure 3B).

The length distribution for the chains of the amylopectin of the wild-type and mutant strains after debranching with isoamylase was confirmed by capillary electrophoresis of the APTS-labelled glucans according to the method described by O'Shea et al., 1996. Significant modification of the distribution of the very short chains is observed in the mutant JV45J, compared to the wild-type strain. A subtractive analysis, in which the differential percentage of the total mass of each oligosaccharide is obtained by subtraction of the chain length distribution for the debranched amylopectins, confirms the enrichment of the range of extra-short glucans (DP 3, 4, 5 at the expense of DP6 to DP11) , found in the mutants. These data confirm the action of the D enzyme *in vivo* on the structure of the amylopectin.

EXAMPLE 4:

Novel functions of the D enzyme

1. Detection of the enzymological defect in the mutants and action of the D enzyme on the polysaccharides.

The detection of the defect was carried out according to a zymogram technique under denaturing conditions (Mouille et al., 1996). In addition, a detailed enzymological study was carried out on crude and

09719978-042501

semipurified extracts, for all known enzymes which can participate in the biosynthesis of starch.

This study involves quantitative and qualitative measurements of enzymatic activities, in parallel to kinetic characterizations and analyses of profiles of elution on Mono-Q anion exchange columns (FPLC chromatography). The enzymes tested are as follows: ADP-glucose pyrophosphorylase, phosphoglucomutase, soluble starch synthetase I, soluble starch synthetase II, granule-bound starch synthetase, branching enzymes (two types), debranching enzymes (pullulanase and isoamylase), phosphorylases and all starch hydrolases which can be detected in zymogram gels containing starch. No qualitative or quantitative difference in these enzymatic activities cosegregated with the mutant gene.

During the production of zymograms under denaturing conditions, the absence of a 62 kD band stained dark red with the iodine was observed in the meiosis products carrying the mutation *stall-1* on a zymogram in the presence of starch or of amylopectin, whereas this 62 kD band appears distinctly in the wild-type segregants (n=75). According to the technique developed by Mouille et al., (1996), the polysaccharide from a gel band was eluted and the product was subjected to NMR analysis. The proton spectrum of the amylopectin incubated had been considerably modified. Specifically, the bimodal proton signal, initially from 5.3 to 5.2 ppm, had been replaced with a monomodal signal, at the same position, of 5.2 ppm, under standard NMR conditions.

2. Purification of the enzyme and glucan transfer activity.

A purification requires 20 litres of culture of a wild-type strain of *Chlamydomonas reinhardtii* in TAP medium (Harris, 1989) for three days in order to obtain a cell density of 2×10^6 cells per ml. After centrifugation at

09719978.042501

3000 rpm for 10 minutes, the cell pellet is put through a French press twice and immediately frozen at -80°C . This thawed crude extract is centrifuged for 20 minutes at 1000 rpm, at 4°C . The extract proteins (350 to 500 mg) are assayed by the Bradford method (Bio-rad assay kit).

The supernatant is precipitated with 5% protamine sulphate (40 μl per ml of extract, 15 minutes in ice), and then centrifuged at 10 000 rpm for 20 minutes at 4°C .

The supernatant (200 to 400 mg of proteins) is injected, using a multi-injection programme, onto a MonoQ ion exchange column (Pharmacia HR 10/10, with a volume of 9 ml, flow rate: $2\text{ ml}\cdot\text{min}^{-1}$) equilibrated in a 50 mM sodium acetate, 2 mM DTT buffer (pH 6 with acetic acid).

The nonretained fraction (40 to 70 mg) undergoes a first precipitation with 30% ammonium sulphate (176 mg/ml) for 45 minutes at 4°C , and is then centrifuged at 1000 rpm for 20 minutes.

The supernatant (30 to 60 mg) is next precipitated to 50% for 45 minutes at 4°C (126 mg/ml), and is then centrifuged at 10 000 rpm for 20 minutes.

The pellet (10 to 20 mg of proteins) is resuspended in 2 ml of 50 mM sodium acetate, 2 mM DTT buffer, pH 6, and then injected onto S 100 filtration gel (FPLC; Pharmacia sephacryl $2.6 \times 60\text{ cm}$; flow rate: $2\text{ ml}\cdot\text{min}^{-1}$; fraction volume: 2 ml; alkyl dextran support bridged with N,N'-methylene bisacrylamide; spherical gel with a diameter of 25 to 75 μm ; fractionation range: 1000 to 10 000) equilibrated in the same buffer. The fractions of interest are collected 30 minutes after the injection, and then detected by revealing the activity on zymograms according to the technique described by Mouille et al., (1996). The enzyme of interest is found in fractions 14 to 26. These fractions are pooled and concentrated using a UnoS12 cation exchange column sold by Bio-Rad (gel with a volume of $15 \times 68\text{ mm}$, grafted with sulphonic acid groups) in a 50 mM sodium acetate, 2 mM DTT buffer. The disproportionating

09719978-042501

enzyme is eluted with a continuous NaCl gradient (50 mM sodium acetate, 1 M NaCl buffer) and the enzyme is recovered in the fractions corresponding to the elution with 50% NaCl.

All the column chromatographies are carried out by FPLC on a Pharmacia LCC-500 apparatus.

The pure enzyme reproduced the effects observed on the amylopectin by proton NMR. The incubation of amylopectin with the pure enzyme led to considerable changes in the distribution for the long chains of the amylopectin (Figure 3D). The action on the amylopectin could be detailed by debranching the incubated product before and after treatment with β -amylase.

As β -amylases are processing enzymes which selectively digest the exterior chains of polysaccharides, the result obtained shows that the major modifications are restricted to the external chains of the polymer. It is important to note that no oligosaccharide is released in the process, while the amount of α -1,6 linkages remains constant. The 62 kD enzyme is, therefore, an α -1,4 glucanotransferase, the function of which is to cleave the α -1,4 linkages present on the external chains of the amylopectin donor in order to transfer them to the nonreducing ends of neighbouring exterior chains of the acceptor. In plants, the only α -1,4 glucanotransferases known to be present in the synthesis of starch are commonly named D enzymes. They are known to act on soluble oligosaccharides at least three glucose residues long (maltotriose) so as to give oligosaccharides of varying length at the expense of the formation of glucose. The reaction consists of cleavage of a donor glucan and transfer to a receptor chain.

The action of the 62 kD enzyme identified was tested, in parallel, on glucose, maltose, maltotriose, maltotetraose, maltopentaose, maltohexaose and maltoheptaose: the enzyme disproportionates with success

09719978, 042504

all the oligosaccharides longer than maltose and glucose, on which it has no action. Its effects on maltotriose have been described in Figure 3E. The very low amounts of maltose in all these cases confirm that the enzyme obeys the rules presented above defining the action of disproportionating enzymes.

The protocol for purifying the D enzyme can be modified, for example according to the following variant:

The supernatant obtained after centrifugation of the crude extract as described in Example 3 is precipitated with protamine sulphate (50 μ l of 10% protamine sulphate per ml of extract, 15 minutes in ice), and then centrifuged at 10 000 rpm for 20 minutes at 4°C.

The supernatant (200 to 400 mg of proteins) is then injected, using a multi-injection programme, onto a MonoQ anion exchange column (Pharmacia HR10/10 with a volume of 9 ml, flow rate: 2 ml.min⁻¹) coupled to a UNO-S12 cation exchange column (BIO-RAD, with a volume of 12 ml, flow rate: 2 ml.min⁻¹). These two columns are equilibrated in a 50 mM sodium acetate, 2 mM DTT buffer (pH 6 with acetic acid). The elution is carried out with a 30 min step at 5% NaCl. The fractions of interest are collected and then detected by revealing the activity on starch zymograms.

300 μ l of sample are loaded onto a maltotriose affinity column (SIGMA: maltotriose immobilized on agarose. Volume: 1 ml) equilibrated in a 50 mM sodium acetate, 2 mM DTT buffer (pH 6 with acetic acid). The column is washed with 2 ml of this same buffer and the elution is carried out with a 50 mM sodium acetate, 1 M NaCl buffer.

0915978-04304
F05240-8265T460

	Total activity	Specific activity
	nmol/min	nmol/min/mg
before affinity column	92.1	2046
after affinity column	13.95	93 000
	Yield	Purification factor
	15%	45%

The activity thus purified occurs at an optimum pH of between pH 5 and pH 7.5, and decreases significantly above pH 9.

3. Incorporation of oligosaccharides onto the external chains of glycogen

The incorporation of labelled maltooligosaccharides onto glycogen provides a further example of the activity of the D enzyme demonstrated on the amylopectin, with the zymogram procedure. The co-elution of the 62 kD band (D enzyme) shows an enzymatic activity found in the zymogram procedures and quantitative tests for purifying the enzyme. A cosegregation between the presence of the 3 activities (production of glucose from maltotriose, modification of amylopectin and incorporation of debranched glucans into glycogen) and the wild-type *STA11* allele in the individuals derived from the crosses between the wild-type and mutant strains of *Chlamydomonas* was also demonstrated.

For demonstrating the incorporation of labelled maltooligosaccharides of controlled length (DP1: glucose to DP7: maltoheptaose), the zymogram procedure described in Example 3 was followed: 100 and 300 µg of crude protein extracts were loaded onto gels containing glycogen, and left to incubate separately with 2 mM DP1 (glucose) to DP7 (maltoheptaose), or without maltooligosaccharides (negative control), overnight at room temperature. The appearance of a 62 kD band with the growing length of the donor substrate

09719978 04541
T05240" 8266T260

shows that the effectiveness of transfer to the external chains of glycogen increases with the length of the donor chain. No labelling is observed when maltotriose is used as a donor substrate, even at very high substrate concentration (20 mM) and after sustained incubation (48 h). Glucans which are longer than maltotetraose therefore define the current substrate preferred for the incorporation reaction. They are thought to be produced *in vivo* during the maturation of pre-amylopectin by isoamylases.

The zymogram system mimics the synthesis of polysaccharide at the surface of the starch granule quite well in that it allows the oligosaccharides to diffuse freely in a large volume of buffer, whereas the polysaccharide is retained in a small volume of the gel, which is where high specific enzymatic activity occurs.

4. Novel polymerase function of the D enzyme.

Oligosaccharides are radioactively labelled with ^{14}C by *in vivo* debranching of the labelled amylopectin. It was verified that the length distribution for the chains in the mixture of the debranched chains corresponded to that shown in Figure 3B.

The incorporation of the oligosaccharides into the amylopectin (Figure 4) or the glycogen of rabbit liver was successfully measured, at physiological concentrations of maltooligosaccharides. Specifically, the D enzyme showed very effective polymerase activity on the glycogen and on the amylopectin. The substrates and products of the reaction were separated by molecular sieve chromatography in TSK-HW-50 gel (glycogen) or in CL2B sepharose.

The incorporation of the labelling of the maltooligosaccharides onto the amylopectin provides a more reliable assay on the activity of the D enzyme, compared to the production of glucose.

It was, moreover, demonstrated that the

0971978-042501

polymerization *in vitro* was located on the external chains of the amylopectin. Specifically, the signal of radioactivity incorporated into the polysaccharide disappears when the amylopectin which has undergone the incorporation of the oligosaccharides is placed in the presence of β -amylase, this being an enzyme specific for the external chains of the amylopectin.

EXAMPLE 5:

Production of transgenic maize plants

A. Production and use of a maize callus as a target for genetic transformation.

The genetic transformation of maize, whatever the method employed (electroporation, biolistics, microfibres, particle gun), generally requires the use of rapidly dividing undifferentiated cells which have conserved an ability to regenerate whole plants. This type of cell composes the embryogenic friable callus (termed type II) of maize.

These calluses are obtained from immature embryos of genotype H1 II or (A188 \times B73), according to the method and on the media described by Armstrong (1994). The calluses thus obtained are multiplied and maintained by successive subculturings every fortnight on the initiation medium.

Plantlets are then regenerated from these calluses by modifying the hormonal and osmotic balance of the cells according to the method described by Vain et al (1989). These plants are then acclimatized in a greenhouse, where they can be crossed or selfpollinated.

B. Use of the particle gun for the genetic transformation of maize.

The preceding paragraph describes the production and regeneration of the transformation cell lines.

0919978-04604

Described here is a method for genetic transformation which leads to the stable integration of the modified genes into the genome of the plant. This method is based on the use of a particle gun. The target cells are fragments of calluses described in paragraph A. Four hours before bombardment, these fragments, with a surface area of 10 to 20 mm², were placed, in a proportion of 16 fragments per dish, at the centre of a Petri dish containing a culture medium identical to the initiation medium, supplemented with 0.2 M of mannitol + 0.2 M of sorbitol. The plasmids carrying the nucleotide sequences to be introduced, such as the cDNA encoding the D enzyme of potato (Takada et al., 1993) or the antisense sequences obtained from this cDNA, are purified on a Qiagen column, following the manufacturer's instructions. They are then precipitated on particles of tungsten (M10) according to the protocol described by Klein et al (1987). The particles thus coated are projected towards the target cells using the gun and according to the protocol described by J. Finner (1992).

The dishes of calluses thus bombarded are then sealed using @Scellofrais, and then cultured in the dark at 27°C. The first subculturing takes place 24 hours later, and then every fortnight for three months on medium identical to the initiation medium supplemented with a selective agent. The selective agents which can be used consist generally of active compounds of certain herbicides (@Basta, @Roundup) or certain antibiotics (hygromycin, kanamycin, etc.).

After three months, or sometimes earlier, calluses are obtained in which the growth is not inhibited by the selection agent, and which are usually and mainly composed of cells resulting from the division of one cell which has integrated into its genetic inheritance one or more copies of the selection gene. The frequency of production of such calluses is approximately 0.8 calluses per dish bombarded.

These calluses are identified, separated, amplified

09349978-04504

and then cultured so as to regenerate plantlets. In order to avoid any interference with nontransformed cells, all these operations are carried out on culture media containing the selective agent.

The plants thus regenerated are acclimatized and then cultured in a greenhouse, where they can be crossed or selfpollinated.

C. Use of *Agrobacterium tumefaciens* for the genetic transformation of maize.

The technique used is described by Ishida et al., 1996.

EXAMPLE 6:

Demonstration of the role of the D enzyme in the degradation of maltooligosaccharides by phosphorylase

It is suggested that, in the bacterium, amylomaltase, an α -1,4 glucanotransferase similar to the D enzyme, increases the production of glucose-1-phosphate by maltodextrin phosphorylase, by generating glucans which are long enough (DP5) to be usable by the phosphorylase (Boos et al., 1998). Measurement of the production of glucose-1-phosphate from maltotriose, maltotetraose, maltopentaose and maltoheptaose (2.5 mM), in the presence of 100 μ g of extracts of the wild-type (137C) and mutant *stall-1* (JV45J) strain of *Chlamydomonas*, demonstrated an at least 5-fold stimulation, in the presence of D enzyme, of the degradation of the maltotetraose and of the maltotriose by the phosphorylase. Since it is known that the production of glucose-1-phosphate from glucan of length DP5 is found both in bacteria and plants, the D enzyme might also facilitate the action of the phosphorylase in plants.

EXAMPLE 7:

Cloning of the sequences encoding the D enzyme

A preliminary gene assay analysis in deploid and

09719978-042504
T05249 82651260

triploid, wild-type and mutant respectively, strains made it possible to establish a correlation between the number of wild-type *STA11* alleles and the amount of corresponding enzyme.

The isolation of genomic sequences encoding the D enzyme of *Chlamydomonas* was carried out according to the following protocol: sequence alignment carried out between *Solanum tuberosum*, *Streptococcus pneumoniae*, *Mycobacterium tuberculosis* and *Clostridium butyricum* made it possible to choose oligonucleotides corresponding to the conserved regions (regions 1 and 2), to be used as primers for PCR reactions. In order to facilitate the cloning of a possible PCR fragment, a 16-nucleotide extension containing the restriction sequences of 3 different enzymes was added in 5' [*EcoRI*, *SacII*, *NotI*].

Region 1	Region 2
P.G.P.Y.G.I.G	R.I.D.H.F.R.G.F
Corresponding degenerated oligonucleotide	Corresponding degenerated oligonucleotide
5' [AGAATTCCGCGGCCGC] CCNGGYSCS TAYGGYATYGG ^{3'}	5' [AGAATTCCGCGGCCGC] RAARCCVGC RAAATGRTCRATVCG ^{3'}

All the PCR reactions were carried out with the *tag* DNA polymerase from GibcoBRL Life Technologies, which is coupled to an antibody and becomes active only after a 3 minute passage at 94°C.

The optimum conditions for the specific amplification of the region of interest are as follows: an $MgCl_2$ concentration of 3 mM and the following programme sequence:

- 3 minutes at 94°C
- 45 seconds at 94°C
- 30 seconds at 62°C
- 1 minute 30 seconds at 72°C

- repetition of steps 2 to 4, 35 times
- 10 minutes at 72°C
- conservation at 4°C.

A band of approximately 1.6 Kb could thus be amplified from genomic DNA.

This PCR product is extracted from a 0.8% TAE gel according to the "DNA Purification Kit" protocol from PROLABO, and placed into the multiple cloning site of the plasmid pBluescript II SK at the NotI site. Transformation of the strain XL1-Blue of *Escherichia coli* made competent then allows the amplification of the clone. Rapid sequencing of the 1.6 Kb (between the T3 and T7 primers) was then carried out according to the Sanger method (SEQ ID No. 1).

The cloning, in the mutant *stall-1*, of the region corresponding to the gene of the D enzyme can be carried out, according to a suitable protocol, in order to determine the nature of the mutation which leads to the absence of the protein in the mutant cell. The demonstration of allele modification specific to the restriction profile of the mutated strain, and the study of the cosegregation of the restriction polymorphism and of the mutation in the segregants of a cross between a wild-type strain and an *STA11* strain may make it possible to correlate definitively the *STA11* gene with the D enzyme.

EXAMPLE 8:

Conditional expression of the mutation

A comparative analysis of the wild-type and mutant *stall-1* strains, under conditions lacking nitrogen or under normal conditions, shows that the expression of the mutant *stall-1* phenotype is partially conditional. This indicates that the expressiveness of the mutation on the phenotype can vary as a function of the physiological conditions, for the same organism. It is possible that these variations in expressiveness of the phenotype are found from one plant

09719978 042501

species to another. It is possible to find conditions under which the drop in the amount of starch does not occur, even though phenotypic modifications are observed (presence of oligosaccharides, modification of the structure of the amylopectin).

The table below gives the results obtained on the phenotypes of the wild-type and mutant strains in the synthesis of transition or storage starch, respectively, using a culture not lacking nitrogen (+N) and a culture lacking nitrogen (-N).

Phenotype of the wild-type and mutant strains in the synthesis of transition or storage starch:

The values listed are the mean of three separate measurements in a single experiment.

Strain	Genotype	Ap λ_{\max}^a		Starch ^b		MOS ^c		Am % ^d	
		+N	-N	+N	-N	+N	-N	+N	-N
C023	+	566	560	1.2	13	0.011	0.018	1	14
C065	+	570	542	0.4	24.7	0.007	0.001	2	15
C035	+	564	554	0.91	22.8	0.012	0.017	5	25
C029	<i>stall-1</i>	576	570	1	1.7	0.45	0.45	7	38
C0137	<i>stall-1</i>	572	564	2	0.83	0.3	0.17	10	25
C0214	<i>stall-1</i>	575	562	0.31	0.78	0.2	0.2	12	24

^a: Ap λ_{\max} , wavelength of the maximum absorbance of an iodinated polysaccharide complex of amylopectin purified by gel filtration.

^b: amount of insoluble polysaccharide, expressed in $\mu\text{g} \cdot 10^{-6}$ cells, purified by sedimentation (measurement by standard assay of the amyloglucosidase).

^c: MOS: amount of soluble maltooligosaccharides, expressed in $\mu\text{g} \cdot 10^{-6}$ cells. $0.5 \mu\text{g} \cdot 10^{-6}$ cells corresponds to a plastidial concentration of 10 mM if all the MOS was to be considered as being maltotriose.

^d: The percentage of amylose in the purified starch was calculated by gel filtration of the dispersed polysaccharides.

BIBLIOGRAPHY

- An G. (1986), Plant Physiol. 81: 86-91
- Armstrong et al., (1994), Maize handbook; M. Freeling, V. walbot Eds, 665-671
- Bensen et al., January 1995, The Plant Cell, Vol. 7, 75-84
- Buléon et al., (1997), Plant Physiol., 115: 949-957
- Das et al., March 1995, The Plant Cell, Vol. 7, 287-294
- Delrue et al., (1992), J. Bacteriol., 174, 3612-3620
- Depicker et al., (1982) J. Mol. Appl. Genet., 1, 561-573
- Finner J. et al., (1992), Plant Cell Reports, 11, 323-328
- Franck et al., (1980) Cell. 21, 285-294
- Fromm M.E., Taylor L.P., Walbot V., (1986) Nature, vol. 319, 791-793
- Gaubier et al., Mol. Gen., 238, 409-418 (1993)
- Ishida et al., (1996), Nature biotechnology, 14, 745-750
- Jouanin, Plant. Sci., 53, 53-63 (1987)
- Harris et al. (1989) San Diego: Academic Press, 25-63
- Haseloff et al., Nature 334, 585-591, 1988
- Kay, Science, (1987) 236, 1299-1302

T03340" 8266T260

- Klein et al., (1987), Nature, 327, 70-73
- McElroy (1991) Mol. Gen. Genet. 231: 150-160
- McClintock, B. 1950, Proc. Natl. Acad. Sci. USA 36, 344-355
- Mouille et al., (1996), Plant Cell 8, 1353-1366
- Ni et al., Pint J., (1995) 7, 661-676
- O'Shea et al. (1996), electrophoresis 17, 681-688
- Sanford J.C., (1988) Trends in Biotechnology, 6, 299-302
- Takaha et al., 1993, J. Biol. Chem. vol. 268, No. 2, 1391-1396
- Takada et al., 1998, Planta, vol. 205, No. 3, 445-451
- Vain et al., (1989), Plant Cell Tissue and Organ Culture, 18, 143-151
- Watson et al., ADN recombinant, [recombinant DNA] Ed. De Boeck University, p 273-292
- Whistler et al., (1967), Starch: chemistry and technology II - Industrial aspects, Academic press, 432-458.

03/1997-04501

CLAIMS

1. Method for modifying the length distribution for the chains of a starch, or for the chains of a glycogen, in which the activity of an α -1,4 glucanotransferase enzyme is increased or decreased in the cells of a plant such that said plant produces a modified starch which differs from the starch produced naturally by the plants, by the length distribution for its external chains, or produces a modified glycogen which differs from the glycogen produced naturally, by the length distribution for its external chains.

2. Method according to claim 1, in which the level of expression of endogenous α -1,4 glucanotransferase enzyme is decreased so as to cause the production of starch comprising an amylopectin which is enriched in chains containing less than 6 glucose residues.

3. Method according to claim 2, comprising the steps consisting in:

a) constructing an expression vector comprising an antisense nucleotide sequence of the gene encoding said α -1,4 glucanotransferase enzyme;

b) transforming a plant cell with said expression vector;

c) regenerating the plant from the cell transformed in step b, said transgenic plant thus obtained producing a starch comprising an amylopectin which is enriched in chains containing less than 6 glucose residues.

4. Method according to any one of the preceding claims, in which said α -1,4 glucanotransferase enzyme is a D enzyme.

5. Method according to any one of the preceding claims, in which said α -1,4 glucanotransferase enzyme is a protein comprising an amino acid sequence encoded by the nucleotide sequence chosen from the sequence SEQ ID No. 1, or a sequence homologous to this sequence.

09719978-04301

6. Plant, or part of a plant, such as in particular potato, wheat, maize or rice, which produces modified starch which differs from the starch produced naturally by the plants, by the length distribution for its external chains, or which produces modified glycogen which differs from the glycogen produced naturally, by the length distribution for its external chains, said plant or part of a plant being obtained by the method according to any one of the preceding claims.

7. Method for obtaining modified starch which differs from the starch produced naturally by the plants, by the length distribution for its external chains, in which:

- the modified starch is extracted from the plants, or parts of plants, according to claim 6;

- or a starch, extracted from plants, or parts of plants, and then solubilized, beforehand, is brought into contact with an α -1,4 glucanotransferase enzyme, in the presence of optionally modified polysaccharides or oligosaccharides.

8. Modified starch obtained according to the method of claim 7.

9. Use of modified starch according to claim 8, for preparing derived products, in particular food products.

10. Products containing a modified starch according to claim 9.

11. Method for obtaining modified glycogen which differs from the glycogen produced naturally, by the length distribution for its external chains, in which:

- the modified glycogen is extracted from the plants, or parts of plants, obtained according to the method of the invention as described above.

- or a glycogen is brought into contact with an α -1,4 glucanotransferase enzyme, in the presence of optionally modified polysaccharides or oligosaccharides.

09719978.042501

12. D enzyme of *Chlamydomonas reinhardtii* purified by the method comprising the steps consisting in:

- centrifuging the *Chlamydomonas reinhardtii* strain;

- precipitating the acellular fraction with protamine sulphate;

- passing the supernatant obtained in the previous step through anion exchange chromatography;

- subjecting the fraction not retained in the previous step to differential precipitation with ammonium sulphate;

- subjecting the supernatant obtained in the previous step to molecular sieve chromatography;

- concentrating the pellet obtained in the previous step, by cation exchange chromatography.

13. Nucleic acid comprising a nucleotide sequence chosen from the sequence SEQ ID No. 1 and a fragment of this sequence encoding a protein having α -1,4 glucanotransferase enzymatic activity.

14. Nucleic acid comprising a sequence which is complementary to the sequence as defined in claim 13.

15. Cloning and/or expression vector comprising a nucleotide sequence as defined in claim 13 or 14.


16. Protein having α -1,4 glucanotransferase enzymatic activity, comprising an amino acid sequence encoded by a nucleotide sequence as defined in claim 13.

17. Use of a nucleic acid comprising a sequence encoding an α -1,4 glucanotransferase enzyme or a sequence which is the antisense sequence to said sequence encoding an α -1,4 glucanotransferase enzyme, for modifying the length distribution for the external chains of starch or of glycogen.

09199704301

09/719978

1/5

**FIG.1**

09/719978

2/5









FIG.2



09/719978

3/5



09/719978


4/5

**FIG.4**

- 2,5 mg/ml amylopectine
- 1 mg/ml amylopectine
- △ 0,25 mg/ml amylopectine

09/719978

5/5

**FIG.5**

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that

#3

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

METHOD FOR OBTAINING MODIFIED POLYSACCHARIDES

the specification of which: *(check one)*

REGULAR OR DESIGN APPLICATION

☐ is attached hereto.

☒ was filed on _____ as application Serial No. _____ and was amended on _____ (if applicable).

PCT FILED APPLICATION ENTERING NATIONAL STAGE

☒ was described and claimed in International application No. PCT/FR99/01446 filed on June 16, 1999 and as amended on _____ (if any).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

PRIORITY CLAIM

I hereby claim foreign priority benefits under 35 USC 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN APPLICATION(S)

Country	Application Number	Date of Filing (day, month, year)	Priority Claimed
FRANCE	9807589	16 JUNE 1998	Yes

(Complete this part only if this is a continuing application.)

I hereby claim the benefit under 35 USC 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 USC 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)

(Filing Date)

(Status--patented, pending, abandoned)

POWER OF ATTORNEY

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from Cabinet Lavoix as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

(b) As a named inventor, I hereby appoint the following attorney(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Robert J. PATCH, Reg. No. 17,355, Andrew J. PATCH, Reg. No. 32,925, Robert F. HARGEST, Reg. No. 25,590, Benoît CASTEL, Reg. No. 35,041, Eric JENSEN, Reg. No. 37,855, and Thomas W. PERKINS, Reg. No. 33,027, c/o YOUNG & THOMPSON, Second Floor, 745 South 23rd Street, Arlington, Virginia 22202.

Address all telephone calls to Young & Thompson at 703/521-2297.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: BALL Steven
(given name, family name)

Inventor's signature [Signature] Date 12/06/00

Residence: 38 rue du 24 août - 59830 Bourghelles FRANCE Citizenship: American FRX

Post Office Address: The same as above

Full name of second joint inventor, if any:
(given name, family name)

Inventor's signature _____ Date _____

Residence: _____ Citizenship: _____

Post Office Address: _____

Full name of third joint inventor, if any:
(given name, family name)

Inventor's signature _____ Date _____

Residence: _____ Citizenship: _____

Post Office Address: _____